Royalty Pharma plc Increase (Decrease) in Finance Receivables
Royalty Pharma plc (RPRX) reported Increase (Decrease) in Finance Receivables of $1.96 billion for the 12-month period ending 2020-12-31, per its 10-K filed 2021-02-24.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInFinanceReceivables · last filed 2021-02-24
- Royalty Pharma plc increase (decrease) in finance receivables for the quarter ending 2020-12-31 was $524.44M, a 24.99% increase year-over-year.
- Royalty Pharma plc increase (decrease) in finance receivables for the quarter ending 2020-09-30 was $498.51M, a 15.91% increase year-over-year.
- Royalty Pharma plc increase (decrease) in finance receivables for the quarter ending 2019-12-31 was $419.59M.
- Royalty Pharma plc increase (decrease) in finance receivables for the quarter ending 2019-09-30 was $430.08M.
- Royalty Pharma plc increase (decrease) in finance receivables for fiscal 2020 was $1.96B, a 18.87% increase from fiscal 2019.
- Royalty Pharma plc increase (decrease) in finance receivables for fiscal 2019 was $1.65B, a 8.13% increase from fiscal 2018.
- Royalty Pharma plc increase (decrease) in finance receivables for fiscal 2018 was $1.52B.
| Period end | Increase (Decrease) in Finance Receivables 3 month | Increase (Decrease) in Finance Receivables 6 month | Increase (Decrease) in Finance Receivables 9 month | Increase (Decrease) in Finance Receivables 12 month |
|---|---|---|---|---|
| 2020-12-31 | $524.44M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $1.02B derived: sum of 2 quarters · filed 2021-02-24 | $1.96B 10-K · filed 2021-02-24 | |
| 2020-09-30 | $498.51M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.44B 10-Q · filed 2020-11-12 | ||
| 2020-06-30 | $937.02M 10-Q · filed 2020-08-12 | |||
| 2019-12-31 | $419.59M derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-24 | $849.68M derived: sum of 2 quarters · filed 2021-02-24 | $1.65B 10-K · filed 2021-02-24 | |
| 2019-09-30 | $430.08M derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.23B 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $799.16M 10-Q · filed 2020-08-12 | |||
| 2018-12-31 | $1.52B 10-K · filed 2021-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |
| Viatris Inc (VTRS) | United States | $20.008B | -0.00 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| Jazz Pharmaceuticals plc (JAZZ) | $15.333B | 16.07 | |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |